Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)

研究成果: Comment/debate同行評審

摘要

Following publication of the original article [1], it was brought to our attention that panel ‘e’ was missing from Fig. 2; the figure has since been corrected in the published article. (Figure presented.).

原文English
文章編號193
期刊BMC Pulmonary Medicine
21
發行號1
DOIs
出版狀態Published - 2021 十二月

All Science Journal Classification (ASJC) codes

  • 肺和呼吸系統醫學

指紋

深入研究「Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)」主題。共同形成了獨特的指紋。

引用此